8-K 1 f25217e8vk.htm FORM 8-K e8vk
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 12, 2006
DYNAVAX TECHNOLOGIES CORPORATION
(Exact name of registrant as specified in charter)
         
Delaware   000-50577   33-0728374
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)
2929 Seventh Street, Suite 100
Berkeley, California 94710
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (510) 848-5100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 

TABLE OF CONTENTS

Item 8.01. Other Events
Item 9.01. Financial Statements and Exhibits
SIGNATURES
INDEX TO EXHIBITS
EXHIBIT 99.1

Table of Contents

Item 8.01. Other Events.
     In a press release dated November 12, 2006, the Company announced additional data from a Phase 2b study involving its TOLAMBA™ investigational therapy.
     The press release dated November 12, 2006, titled “Dynavax Reports New TOLAMBA Data at ACAAI Meeting,” is attached hereto as Exhibit 99.1 and is herein incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
     
Exhibit No.   Description
99.1
  Press Release, dated November 12, 2006, entitled “Dynavax Reports New TOLAMBA Data at ACAAI Meeting.”

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
         
  Dynavax Technologies Corporation
 		  
Dated: November 13, 2006  By:   /s/ Deborah A. Smeltzer    
    Deborah A. Smeltzer, Vice President,   
    Operations and Chief Financial Officer   

 

Table of Contents

         
INDEX TO EXHIBITS
     
Exhibit    
Number   Description
99.1
  Press Release, dated November 12, 2006, entitled “Dynavax Reports New TOLAMBA Data at ACAAI Meeting.”